Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512135 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
A Phase 3 study, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 801
- Enrollment target
NCT00512135 is a Phase 3 study that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 801 participants.
The verdict
NCT00512135, a Phase 3 study, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 801 participants
- Enrollment target
Study Summary
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.
Interventions
- DRUG IncobotulinumtoxinA (Xeomin) (20 units)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2007-06-18 |
| Est. Completion | 2009-12-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512135
The ClinicalTrials.gov registry entry for NCT00512135 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IncobotulinumtoxinA (Xeomin) (20 units) is the first listed.
NCT00512135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512135 about?
NCT00512135 is a clinical study titled "Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines". The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e...
What is the current status of trial NCT00512135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 801 participants. The study started on 2007-06-18. Estimated completion is 2009-12-28.
What interventions are being tested in trial NCT00512135?
The interventions under investigation include: IncobotulinumtoxinA (Xeomin) (20 units) (DRUG).
Who is sponsoring clinical trial NCT00512135?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.